Members Sought for Director's Consumer Liaison Group: NCI

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 7
Volume 6
Issue 7

BETHESDA, Md--The NCI is calling for nominations for a new initiative--the Director's Consumer Liaison Group (DCLG). This group will help the NCI increase the representation of the cancer advocacy community on NCI advisory committees and increase the involvement of consumer advocates in program and policy development.

BETHESDA, Md--The NCI is calling for nominations for a new initiative--theDirector's Consumer Liaison Group (DCLG). This group will help the NCIincrease the representation of the cancer advocacy community on NCI advisorycommittees and increase the involvement of consumer advocates in programand policy development.

It will consist of 15 consumer advocates brought together from manyadvocacy communities. To be eligible for the DCLG, a nominee must be involvedin the cancer experience as a cancer survivor, a person affected by thesuffering and consequences of cancer, or a professional/volunteer who workswith survivors or those affected.

Nominations can be made by organizations, including local/regional andnational groups, or by individuals, including self-nominations.

For more information and to receive a nomination package, send yourname, advocacy organization affiliation (if any), and address to the Officeof Liaison Activities, NCI, c/o Palladian Partners, 7315 Wisconsin Avenue,Suite 440W, Bethesda, MD 20814. Fax: 301-986-5047. Nominations must bepostmarked by September 15, 1997.

Recent Videos
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content